Effect of etidronate on urinary Calcium/Creatinin ratio in postmenopausal women: A prospective, randomized, placebo controlled study

Basit Öğe Kaydı
dc.authorscopusid6603257434
dc.authorscopusid56634649300
dc.authorscopusid6602510972
dc.authorscopusid6506610415
dc.authorscopusid6506315065
dc.authorscopusid55886237400
dc.contributor.authorKucuk S.
dc.contributor.authorGokdeniz R.
dc.contributor.authorAtmaca R.
dc.contributor.authorUryan I.
dc.contributor.authorBuhur A.
dc.contributor.authorTaskin O.
dc.date.accessioned2024-08-04T20:00:53Z
dc.date.available2024-08-04T20:00:53Z
dc.date.issued1999
dc.departmentİnönü Üniversitesien_US
dc.description.abstractThere are both histomorphometric and nonhistomorphometric studies confirming that etidronate reduces bone resorption. In this study, we have examined urinary Calcium/Creatinine ratio (uCa/Cr) as a biochemical marker of bone turnover to show the effectiveness of etidronate and whether it could be used as a follow-up parameter of treatment. Eighty-one postmenopausal women aged 40 to 65 included into the study to investigate the effects of etidronate on uCa/Cr in a prospective, randomised, placebo controlled clinical trial. All necessary criteria matched 81 women were divided into 3 groups at random, each group consisted of 27 patients. Prior to treatment, uCa/Cr was calculated from all subjects 3 hours after drinking 1 liter of water in the morning. Twenty seven (33.3%) women were randomised to oral doses of etidronate (400 mg/day for two weeks followed by drug free period of 10 weeks), twenty seven women to etidronate (400 mg/day for two weeks) plus calcium (1000 mg/day) for the following 10 weeks and twenty seven women to placebo (Fe, 50 mg/day) for 12 weeks. After 12 weeks of treatment, uCa/Cr declined significantly in the etidronate group from 0.118±0.064 to 0.053±0.021, in etidronate+calcium group from 0.08±0.03 to 0.06±0.015 ((p=0.004) and (p=0.005), respectively). In the placebo group no significant change was observed (p=0.03). In conclusion, etidronate is effective in postmenopausal women and the effectiveness of treatment may be followed up by measuring uCa/Cr which is a simple and cheap parameter of determining the effectiveness of etidronate in prevention of osteoporosis. However, since there are contradictory findings concerning uCa/Cr exist, larger clinical and prospective studies should be carried out.en_US
dc.identifier.endpage687en_US
dc.identifier.issn1300-0144
dc.identifier.issue6en_US
dc.identifier.scopus2-s2.0-0032695603en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage683en_US
dc.identifier.urihttps://hdl.handle.net/11616/91082
dc.identifier.volume29en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.relation.ispartofTurkish Journal of Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectEditronateen_US
dc.subjectHormone replacement therapyen_US
dc.subjectUrinary Calcium/Creatinin ratioen_US
dc.titleEffect of etidronate on urinary Calcium/Creatinin ratio in postmenopausal women: A prospective, randomized, placebo controlled studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu